DuPont launches AmberChrom SIL silica gel for high-purity peptide drug manufacturing

DuPont has introduced AmberChrom SIL silica gel, a new reverse phase silica-based chromatography media designed to improve the purification of peptide therapeutics such as GLP-1 receptor agonists. This innovation supports biopharmaceutical manufacturers in meeting strict purity and yield requirements during peptide drug production, especially for treatments addressing diabetes, obesity, and oncology. AmberChrom SIL can be integrated with other DuPont chromatography products to optimize purification workflows from crude mixtures to final polishing stages, enhancing efficiency and scalability in manufacturing. The product aims to help manufacturers maintain consistent quality as demand for peptide therapies grows.

DuPont de Nemours Inc (DD) trades at USD 134.09 on Pluang as of Oct 22, 2026 20:12 WIB, with a slight 1-day decline of 0.04%. The stock shows strong investor interest with 100% buy orders on the platform and holds a market cap of $18.12 billion. This stable trading environment coincides with DuPont's launch of AmberChrom SIL silica gel, which aims to enhance peptide therapeutic manufacturing processes.